Holen Sie sich die Stockscreener-App
18.52
0.00%
0.00
Schlusskurs vom Vortag:
$18.52
Offen:
$18.75
24-Stunden-Volumen:
337.99K
Relative Volume:
0.84
Marktkapitalisierung:
$1.03B
Einnahmen:
$29.71M
Nettoeinkommen (Verlust:
$-69.15M
KGV:
-16.46
EPS:
-1.1251
Netto-Cashflow:
$-52.28M
1W Leistung:
-4.68%
1M Leistung:
-31.20%
6M Leistung:
+6.62%
1J Leistung:
+49,685%
1-Tages-Spanne:
$17.93
$18.82
1-Wochen-Bereich:
$17.93
$20.08
52-Wochen-Spanne:
$14.72
$34.19
Aktis Oncology Inc Stock (AKTS) Company Profile
Firmenname
Aktis Oncology Inc
Sektor
Branche
Telefon
978-237-4380
Adresse
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
18.52 | 1.08B | 29.71M | -69.15M | -52.28M | -1.1251 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-02-03 | Eingeleitet | BofA Securities | Buy |
| 2026-02-03 | Eingeleitet | JP Morgan | Overweight |
| 2026-02-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-02-03 | Eingeleitet | TD Cowen | Buy |
| 2024-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-02 | Bestätigt | Craig Hallum | Buy |
| 2021-01-15 | Bestätigt | Craig Hallum | Buy |
| 2019-09-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | Bestätigt | Craig Hallum | Buy |
| 2019-02-05 | Bestätigt | Craig Hallum | Buy |
| 2019-02-05 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | Eingeleitet | Craig Hallum | Buy |
| 2018-11-30 | Eingeleitet | Lake Street | Buy |
| 2018-06-22 | Eingeleitet | Loop Capital | Buy |
| 2018-02-09 | Eingeleitet | Drexel Hamilton | Buy |
Alle ansehen
Aktis Oncology Inc Aktie (AKTS) Neueste Nachrichten
Aktis Oncology initiates phase 1b trial for lung cancer drug By Investing.com - Investing.com Canada
A cancer drug will be tested in lung cancer; its prostate-cancer trial is enrolling. - Stock Titan
Aktis Oncology (AKTS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Form 144 AKTIS ONCOLOGY INC For: 26 September By Investing.com - Investing.com Nigeria
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aktis Oncology (AKTS) medical chief exercises options and sells shares under a trading plan. - Stock Titan
After selling 50,000 shares in July, an Aktis Oncology (AKTS) officer plans another sale. - Stock Titan
Aktis Oncology (NASDAQ:AKTS) Shares Down 8.6%Here's What Happened - MarketBeat
Aktis Oncology (AKTS) Gains 2.64% as Shares Push Back Toward $22MFI Oversold - dars.gov.et
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Tidal Investments LLC Acquires New Position in Aktis Oncology $AKTS - MarketBeat
Aktis Oncology at Morgan Stanley conference: platform bets and capital strength - Investing.com Canada
AKTS: Multi-tumor radiopharmaceuticals advance in phase I, backed by platform innovation and strong funding - TradingView
symbol__ Stock Quote Price and Forecast - CNN
AKTS Initiated Coverage by Oppenheimer -- Rating Set to Outperform - GuruFocus
Two New York investor events will include Aktis Oncology's CEO - stocktitan.net
Oppenheimer initiates Aktis Oncology stock rating at Outperform By Investing.com - Investing.com India
Oppenheimer initiates Aktis Oncology stock rating at Outperform - Investing.com
Aktis Oncology (NASDAQ:AKTS) Trading Down 7.3%Should You Sell? - MarketBeat
Wellington Management Group LLP Takes $63.37 Million Position in Aktis Oncology $AKTS - MarketBeat
Aktis Oncology $AKTS Shares Purchased by BlackRock Inc. - MarketBeat
AKTS Q2 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Net LossQuarterly Profit Report - vinanet.vn
Jupiter Topco LLC Invests $42.36 Million in Aktis Oncology $AKTS - MarketBeat
Great Lakes Advisors LLC Takes $1.41 Million Position in Aktis Oncology $AKTS - MarketBeat
Blue Owl Capital Holdings LP Sells 91,129 Shares of Aktis Oncology $AKTS - MarketBeat
Aktis (AKTS) Earnings Snapshot: EPS Comes in Below Forecast in the Latest Session; Closing Reaction: The Share Price Sheds 4.08%Margin Guidance - vinanet.vn
AKTIS ONCOLOGY INC : WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $35 - Bitget
Wedbush initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com South Africa
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - Yahoo Finance
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target - marketscreener.com
BMO initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com Canada
AKTS Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Aktis Oncology (AKTS) Slips to $24.72 as Shares Trade Within Established RangeSynthetic Long - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Oncology Pipeline InvestmentLow Growth Earnings - vinanet.vn
Aktis Oncology, Inc.: Target Price Consensus and Analysts Recommendations | AKTS | US01021M1045 - marketscreener.com
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
AKTS SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations - marketbeat.com
Aktis Oncology Q2 EPS misses estimate, sales beat consensus - scanx.trade
Aktis: Q2 Earnings Snapshot - KING5.com
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 - The Manila Times
Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029 - Stock Titan
Aktis Oncology (AKTS) Gains 2.94% as Shares Approach Key Resistance at $25.34Fade Trade - dars.gov.et
Aktis Oncology (AKTS) Slips 1.5% as Shares Hover Above Key Support at $20.64Donchian Channel - careplusvn.com
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share Highlights Pre-Revenue ChallengesDividend Cut Risk - dars.gov.et
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share, Yet Shares Climb 2.72%Profit Recovery Report - dars.gov.et
AKTS Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline - dars.gov.et
Insider Selling: Aktis Oncology (NASDAQ:AKTS) Director Sells 4,856 Shares of Stock - MarketBeat
Finanzdaten der Aktis Oncology Inc-Aktie (AKTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aktis Oncology Inc-Aktie (AKTS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Czibere Akos | Chief Medical Officer |
Sep 23 '26 |
Sale |
20.69 |
12,500 |
258,621 |
0 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):